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1. Introduction
  Severe rhabdomyolysis is an uncommon but potentially 
fatal complication of dengue fever that is not well 
characterised and may be underreported. Dengue fever, a 
mosquito-borne flavivirus endemic in Southeast Asia and 
Western Pacific regions, has been increasingly reported 
worldwide[1]. With the resurgence and continued rise of 
dengue cases in endemic regions, physicians must maintain 
not only a high index of suspicion for the diagnosis but also 
an awareness of the less common but serious complications 
of dengue. Here, we would like to report a patient who 
presented with severe rhabdomyolysis secondary to dengue 
fever with a serum creatine kinase (CK) of 742 900 U/L on 
admission.
2. Case report
  An active 50 year old Chinese male with a medical history 
of hypertension and hyperlipidemia on daily long term 
amlodipine 5 mg and simvastatin 10 mg, presented with 
fever of 5 d duration associated with myalgia. In the initial 
2 d of illness, his symptoms were mild and he proceeded 
with a mountain hike in Malaysia. He reached the summit of 
2 000 feet above sea level with little difficulty. Upon return, 
his symptoms worsened and he developed abdominal pain 
and vomiting 2 d prior to admission. No medications were 
recently initiated and the patient denied illicit drug use. 
There was no history of fall or injury. There was also no 
family history of muscle diseases.
  On admission, the patient was alert and ambulant. He was 
noted to be tachypnoeic with a respiratory rate of 35 breaths/
min, a blood pressure of 174/85 mmHg and a pulse rate of 
85 beats/ min. His laboratory tests are as follow: serum CK: 
742 900 U/L, creatinine: 1 036 mmol, arterial bicarbonat: 
7.4 mmol/L. The diagnosis of dengue fever was confirmed 
with both a positive dengue IgM and a positive dengue virus 
PCR. His blood and urine cultures demonstrated no growth of 
organisms and the leptospiral and rickettsia serologies were 
negative. His platelet count on admission was 33×103/毺L.
Soon after admission, he was transferred to the intensive 
care unit (ICU) for continuous renal replacement therapy. 
  However, within 24 h, his condition deteriorated in the 
ICU. He required both inotropic and ventilatory support. 
His stay was complicated by the development of acute 
compartment syndrome of bilateral lower extremities 
from severe rhabdomyolysis and likely intramuscular 
bleed, acute liver failure and disseminated intravascular 
coagulation. He also had seizures from generalised cerebral 
edema and gastrointestinal bleeding requiring massive 
blood tranfusions. On day 19 of his illness, he suffered a 
cardiorespiratory collapse and eventually demised.
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3. Discussion
  Severe rhabdomyolysis is an uncommon complication of 
dengue[2-5]. Its pathogenesis has remained elusive although 
the release of cytokines, particularly tumour necrosis factor, 
has been implicated[6-9]. The causal relationship between 
dengue and rhabdomyolysis is often confounded by the 
presence of established shock and multiorgan complications 
of the critically ill patient. However, in our patient, it 
was clear that the rhabdomyolysis occurred before the 
development of shock, suggesting that this may be a true 
complication of dengue.           
  It is also interesting to note that in our patient, there was 
a history of significant physical activity early in his illness. 
Acharya et al[2] reported a patient with rhabdomyolysis from 
dengue who was involved in labour work during the period 
of illness while Lim et al[3] reported a case of readmission 
for myalgia with rhabdomyolysis following resumption of 
exercise 2 d after a prior hospital discharge for dengue fever. 
It seems plausible that strenuous physical activity may be a 
potential risk factor for severe rhabdomyolysis peri-illness. 
Hence, it may be prudent to advise dengue patients to avoid 
aggressive physical activity during the period of acute 
illness or convalescent phase. This is especially so for those 
who are engaged in laboriously demanding occupations or 
patients who enjoy strenuous recreational activities. 
  We concede that our patient was on long term low 
dose statin medication. However, fatal rhabdomyolysis 
associated with statins is rare[10] and appears to be dose 
dependent[11,12]. Studies have also attempted to look at 
exertion-induced muscle injury in patients on statins. In a 
study by Thompson et al, CK levels were 62% to 77% higher 
after treadmill exercise in patients on lovastatin versus 
placebo[13]. Nevertheless, exertion-triggered rhabdomyolysis 
in patients on statin therapy resulting in acute renal failure 
requiring dialysis is extremely rare and the levels of CK 
reported were generally far below that of our patient[14]. 
Exercise and rhabdomyolysis has also been well described. 
However, exercise –induced rhabdomyolysis leading to 
dialysis-requiring acute renal failure is rare too. In a series 
by Sinert et al, none of the 35 patients with pure exercise-
induced rhabdomyolysis developed acute renal failure in 
the absence of nephrotoxic cofactors[15] In addition, other 
reports of severe exercise-induced rhabdomyolysis have 
implicated predisposing factors such as the concomitant use 
of performance enhancing compounds[16], sickle cell trait[17] 
and genetic factors[18].
  Hence, given the clinical picture, simvastatin or exercise 
alone was unlikely to have accounted for our patient’s 
extreme level of CK. To our knowledge, it is the highest level 
of CK reported in a dengue patient with rhabdomyolysis. 
On the other hand, it is possible that the unfortunate 
combination of all 3 factors - dengue virus infection, 
coupled with statin use and exercise led to his fatal 
rhabdomyolysis. 
  In conclusion, severe rhabdomyolysis is a rare but 
potentially lethal complication of dengue. The mechanism 
as well as risk factors for this complication including 
exercise peri-illness or concomitant statin use, remains to 
be determined. In Southeast  Asia, dengue is endemic, statin 
use is common, and there is an increasing number of people 
engaging in endurance sports, with many more involved in 
physically demanding occupations, Thus, physicians must 
be aware of this complication, and possibly the ‘high-risk’ 
patient profile as described in our report. We hope that 
future studies may continue to further our understanding of 
this enigmatic disease, thereby leading to improvements in 
patient care and clinical outcomes.  
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